TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean change from baseline in the frequency of moderate to severe vasomotor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in the severity of moderate to severe vasomotor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expired fraction of oxygen at the end of intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Successful rate of residual shunt <5mm at 30-days postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of severe complications during 360-day post ASD closure operative
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiometabolic outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in the Ashworth Scale (AS) Score of Plantar Flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Investigator's Global Impression of Change of Plantar Flexor Spasticity Scale (GICS-PF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: urinary functional outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: VO2 max (maximal oxygen consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary function testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: direct medical cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: tissue coverage per strut level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Modified Baron Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Type 2 Diabetes Mellitus (T2DM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: absolute lymphocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the curve of the evolution of appetite sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average of the appetite sensation during the 60 minutes after intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of energy consumed during the ad-libitum meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and severity of ocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of peripheral sensory neuropathy (PSN) grade 2, 3 and 4
Endpoint domain: Adverse events/effects
Primary endpoint: Breathlessness Beliefs Questionnaire-BBQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correlation of serial high-speed MRSI of [tCho] with pCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of decrease of acute GVHD grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peak Slip Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk Angle at Touchdown After Tripping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder complex kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder associated muscular activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily diet and activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of minutes with portage skin-to-skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1c (A1C) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean daily combined symptom medication score (SMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak torque normalized by body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VOCs detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight & Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat intake (percent calories from fat and saturated fat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concordant allograft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Balance During a Dynamic Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Balance During a Static Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Human Inflammation Multi analyte profile (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Unified Dyskinesia Rating Scale (UDysRS) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: serum 25(OH)-vitamin D concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: presence of solar elastosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: local immunosuppression in skin biopsy samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Symptomatic Intracerebral Hemorrhage Within 36 Hours of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CIU symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-Implant Mucosal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correlation between Arterial and end-tidal carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Fick Cardiac Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 30-day Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in WOMAC Osteoarthritis Index LK 3.1 subscale score for pain and physical function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC) of TFV-DP and FTC-TP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average steady-state plasma deoxyguanosine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroencephalography P300
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: liver function (blood)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Alzheimer disease assessment scale (ADAS-cog)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in activities of daily living scale (ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in neuropsychiatric inventory (NPI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in geriatric depression scale (GDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modified Rankin Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in verbal abilities at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in communication ability at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in working memory at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in nausea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduced adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants Who Did Not Require an IV Anesthetic Drug
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: aortic calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient positioning effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative haemodynamic stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight Gain Per Week of Observation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of opioid titration order sheet
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of opioid titration order sheet
Endpoint domain: Resource use
Primary endpoint: Frequency and severity of voriconazole related adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of Exercises: Ease Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of Exercises: Utility Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Pre-dose FEV1 at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Toxicity including GVHD and marrow aplasia
Endpoint domain: Adverse events/effects
Primary endpoint: Infant Health Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in Hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sonographic measurement of multifidus thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximal percentage decrease in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the curve (AUC) of time adjusted percent decrease in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fugl-Meyer Score Change Immediately Following Study Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Score Change at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in total score of UPDRS Part II (Activities of Daily Living)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in total score of UPDRS Part III (Motor Examination)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Assessed for Clinical Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of subclinical hyperthyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Differentially expressed genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of creatinine in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 6 min. walk test (6-WT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spirometry measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hemodynamic measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-care management in Chronic Kidney Disease
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in 6 minute walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow-Mediated Dilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peripheral Blood Levels of Inflammatory and Coagulation Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival with no or minimal neurological sequel
Endpoint domain: Mortality/survival
Primary endpoint: Diagnostic accuracy of cardiac CT perfusion techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of life at short term
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life at long term
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: incidence of osteonecrosis of the Jaw (ONJ)
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of skeletal related events (SREs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants with First Cycle Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With One or More Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Adverse Events of Clinical Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants That Experienced a Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Median Overall Survival (OS) of Phase II Patients
Endpoint domain: Mortality/survival
Primary endpoint: sustained culture conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Wound Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Major cerebrovascular event
Endpoint domain: Mortality/survival
Primary endpoint: presence of a recurrent patellar dislocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: radiological reduction of the trochlear bump postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Lateral condyle index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Success of IVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Th 17 cytokines (Il-17 and Il-22)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SDF parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acceptability of intervention participation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: intervention fidelity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence, frequency, and severity of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: rate of first ICU acquired bloodstream infection
Endpoint domain: Adverse events/effects
Primary endpoint: Longitudinal Myocardial Strain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first event of adjudicated CV death
Endpoint domain: Mortality/survival
Primary endpoint: Time to first event of adjudicated HHF
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in perivascular space volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in DTI fractional anisotropy on voxel-wise basis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in a summary measure of arterial pulsatility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in perivascular lactate measured by MR spectroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in cerebrovascular reactivity on a voxel-wise basis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Hepatitis B Virus (HBV) DNA Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of successful manufacture and expansion of CAR T cells
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Smoking Quit Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects experiencing adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of signs and symptoms of blepharitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PET imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Agitation Behavior Mapping Instrument (ABMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor development parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental development parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrocardiogram changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Observed Plasma Concentration of Hyoscine Butylbromide (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC Time Zero to Times of Last Quantifiable Concentration (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical Intraepithelial Neoplasia (CIN) grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Severe exacerbation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to NMES therapy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Diagnostic value of MicroRNA 210
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Compression depth %
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest recoil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survivorship of the Encore Reverse Shoulder Prosthesis
Endpoint domain: Mortality/survival
Primary endpoint: Executive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mullen Scales of Early Learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in microarray gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of essential amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphological changes of lacrimal sac lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ad libitum energy consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of the First Off-treatment Cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Hormone-refractory Diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Dose Hold, Dose Reduction, or Treatment Withdrawal for Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Internal fit of the crown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of beneficial effect of the treatment X
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to All-Cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Time to First COPD Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Binding of [11C] ABP688 to mGlu5 receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood levels of [11C] ABP688
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New onset atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Carbon 13 Oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSI status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes